期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 15, 期 4, 页码 772-777出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2018.1560918
关键词
herpes zoster; older adults; immune responses; zoster vaccine live; recombinant zoster vaccine; adjuvants; vaccinology; viral
资金
- GlaxoSmithKline
- Merck, Sharp Dohme
There are two licensed herpes zoster vaccines. One is a live vaccine (ZVL) based on an attenuated varicella-zoster virus (VZV). The other is a recombinant vaccine (RZV) based on the VZV glycoprotein E (gE) combined with AS01B, a multicomponent adjuvant system. RZV is superior to ZVL in efficacy, and differs from ZVL in that protection is not diminished by the age of the vaccinee and has not waned significantly during 4 years of follow-up. Immunologic studies demonstrated higher peak memory and persistence of T cell responses in RZV compared with ZVL recipients. RZV recipients also showed development and persistence of polyfunctional T cell responses. Taken together, we conclude that the immunologic data parallel and support the higher efficacy over time of RZV compared with ZVL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据